Adrixetinib clinical trials
How each study uses adrixetinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the adrixetinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Qurient Co., Ltd. (3) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test adrixetinib.
- Jul 2027Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid LeukemiaPhase 1 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses adrixetinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host DiseaseRecruitingPhase 1Qurient Co., Ltd.NCT07138196Written as Adrixetinib
- Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingPhase 1Mayo ClinicNCT06712810Written as Axl/Mer/CSF1R Inhibitor Q702
- Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT06445907Written as Q702
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid TumorsActive, not recruitingPhase 1/2Qurient Co., Ltd.NCT05438420Written as Q702
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid TumorCompletedPhase 1Qurient Co., Ltd.NCT04648254Written as Q702
Codes
What other systems call adrixetinib · ClinicalTrials.gg INT016953
- UNII (FDA) JIJ7I9XO8BADRIXETINIBOne source FDA
- NCI Thesaurus C199002AdrixetinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JIJ7I9XO8B | ADRIXETINIB | One source FDA |
| NCI Thesaurus | C199002 | Adrixetinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.